Profile data is unavailable for this security.
About the company
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene is initially in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its lead candidate, BOND-003 is a targeted oncolytic intravesically delivered immunotherapy agent that is in Phase II for the treatment of Bacillus Calmette Guerin (BCG) unresponsive and intermediate risk NMIBC disease. Its other product candidate CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).
- Revenue in USD (TTM)539.00k
- Net income in USD-72.33m
- Incorporated2017
- Employees61.00
- LocationCG Oncology Inc400 Spectrum Center Drive, Suite 2040IRVINE 92618United StatesUSA
- Phone+1 (949) 288-6298
- Fax+1 (302) 531-3150
- Websitehttps://www.cgoncology.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Harmony Biosciences Holdings Inc | 617.51m | 137.70m | 1.70bn | 246.00 | 12.89 | 3.29 | 10.46 | 2.75 | 2.32 | 2.32 | 10.39 | 9.08 | 0.7906 | 25.72 | 9.34 | 2,510,207.00 | 17.63 | 7.46 | 20.83 | 9.08 | 79.28 | 80.58 | 22.30 | 10.46 | 3.07 | 31.38 | 0.2694 | 0.00 | 32.93 | -- | -28.99 | -- | -25.31 | -- |
Protagonist Therapeutics Inc | 314.95m | 162.11m | 1.74bn | 124.00 | 12.04 | 3.10 | 10.65 | 5.51 | 2.46 | 2.46 | 5.25 | 9.56 | 0.7248 | -- | 2.10 | 2,812,080.00 | 37.30 | -35.90 | 40.23 | -41.36 | -- | -- | 51.47 | -332.81 | -- | -- | 0.00 | -- | 125.73 | 14.17 | 38.02 | -- | 4.62 | -- |
Inhibrx Inc | 1.78m | -271.16m | 1.78bn | 166.00 | -- | 145.30 | -- | 1,000.99 | -5.35 | -5.35 | 0.0358 | 0.235 | 0.0066 | -- | 7.51 | 10,740.96 | -99.40 | -77.06 | -123.13 | -93.91 | -- | -- | -15,116.15 | -1,590.91 | -- | -12.67 | 0.9474 | -- | -17.88 | -26.85 | -66.20 | -- | 26.30 | -- |
CG Oncology Inc | 539.00k | -72.33m | 1.82bn | 61.00 | -- | 3.20 | -- | 3,377.56 | -1.13 | -1.13 | 0.0084 | 8.54 | -- | -- | -- | 8,836.07 | -- | -- | -- | -- | -- | -- | -10,551.39 | -- | -- | -- | 0.00 | -- | 6.81 | -- | -54.83 | -- | -- | -- |
Fusion Pharmaceuticals Inc | 2.04m | -104.28m | 1.82bn | 113.00 | -- | 7.52 | -- | 892.56 | -1.42 | -1.42 | 0.0279 | 2.85 | 0.0069 | -- | 45.84 | 18,053.10 | -35.33 | -35.45 | -37.76 | -38.55 | -- | -- | -5,111.57 | -7,206.24 | -- | -- | 0.1704 | -- | 41.55 | -- | -8.32 | -- | 28.21 | -- |
Ardelyx Inc | 159.11m | -65.81m | 1.82bn | 267.00 | -- | 12.08 | -- | 11.46 | -0.2883 | -0.2883 | 0.7007 | 0.6449 | 0.5689 | 3.20 | 7.90 | 595,917.60 | -23.53 | -46.14 | -29.95 | -57.32 | 85.30 | 88.15 | -41.36 | -240.87 | 4.36 | -9.86 | 0.3982 | -- | 138.61 | 116.66 | 1.70 | -- | 2.04 | -- |
Syndax Pharmaceuticals Inc | 0.00 | -240.63m | 1.84bn | 112.00 | -- | 3.74 | -- | -- | -3.22 | -3.22 | 0.00 | 5.79 | 0.00 | -- | -- | 0.00 | -47.99 | -27.90 | -51.84 | -30.15 | -- | -- | -- | -324.34 | -- | -- | 0.00004 | -- | -- | -- | -40.19 | -- | -- | -- |
Novavax Inc | 996.61m | -398.71m | 1.89bn | 1.54k | -- | -- | -- | 1.90 | -3.18 | -3.18 | 8.46 | -6.18 | 0.6882 | 14.75 | 14.85 | 645,890.50 | -27.53 | -46.06 | -460.95 | -269.57 | 63.04 | -- | -40.01 | -75.94 | 0.8843 | -27.04 | -- | -- | -50.36 | 95.68 | 17.16 | -- | 108.28 | -- |
Sana Biotechnology Inc | 0.00 | -308.61m | 1.90bn | 328.00 | -- | 5.07 | -- | -- | -1.53 | -1.53 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -43.21 | -38.99 | -48.50 | -42.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.11 | -- | 112.71 | -- |
Keros Therapeutics Inc | 234.00k | -160.30m | 1.90bn | 141.00 | -- | 4.20 | -- | 8,138.37 | -5.14 | -5.14 | 0.0075 | 12.59 | 0.0005 | -- | -- | 1,720.59 | -36.84 | -35.95 | -38.35 | -38.07 | -- | -- | -68,505.13 | -1,237.26 | -- | -- | 0.00 | -- | -- | -56.77 | -46.15 | -- | 62.57 | -- |
Ginkgo Bioworks Holdings Inc | 208.70m | -853.81m | 1.91bn | 1.22k | -- | 1.78 | -- | 9.14 | -0.4347 | -0.4347 | 0.1061 | 0.4855 | 0.1044 | -- | 3.82 | 171,344.00 | -42.70 | -- | -46.94 | -- | 80.43 | -- | -409.12 | -- | -- | -- | 0.00 | -- | -47.36 | -- | 57.58 | -- | -- | -- |
Agios Pharmaceuticals Inc | 29.40m | -352.62m | 1.94bn | 383.00 | -- | 2.60 | -- | 65.92 | -6.31 | -6.31 | 0.5257 | 13.11 | 0.0294 | 0.1715 | 11.24 | 76,770.23 | -35.24 | -29.54 | -37.04 | -31.88 | 89.95 | -- | -1,199.26 | -3,826.10 | 12.39 | -- | 0.00 | -- | 88.36 | -22.25 | -51.89 | -- | -32.23 | -- |
Catalyst Pharmaceuticals Inc | 411.35m | 65.12m | 1.95bn | 167.00 | 30.63 | 3.47 | 19.30 | 4.73 | 0.5384 | 0.5384 | 3.60 | 4.76 | 0.7806 | 3.60 | 8.76 | 2,463,156.00 | 12.36 | 25.42 | 14.19 | 29.81 | 86.74 | 85.63 | 15.83 | 30.87 | 4.83 | -- | 0.00 | 0.00 | 85.90 | 280.39 | -14.05 | -- | 20.21 | -- |
Holder | Shares | % Held |
---|---|---|
Ally Bridge Group (NY) LLCas of 25 Jan 2024 | 2.49m | 3.75% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 2.19m | 3.30% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 1.54m | 2.32% |
BlackRock Advisors LLCas of 31 Mar 2024 | 535.82k | 0.81% |
BlackRock Investment Management (UK) Ltd.as of 31 Mar 2024 | 258.47k | 0.39% |
TimesSquare Capital Management LLCas of 31 Mar 2024 | 224.07k | 0.34% |
Charles Schwab Investment Management, Inc.as of 31 Mar 2024 | 169.35k | 0.26% |
BlackRock Financial Management, Inc.as of 31 Mar 2024 | 101.87k | 0.15% |
BlackRock Investment Management LLCas of 31 Mar 2024 | 80.90k | 0.12% |
The Bank of New York Mellon Corp. (Investment Management)as of 31 Mar 2024 | 47.00k | 0.07% |